The Largest Companies in Biotechnology & Pharmaceuticals Industry Value and Market Capitalization, Revenue, Income, Number of Employees - CSIMarket
Healthcare Sector

The Largest Companies in Biotechnology & Pharmaceuticals Industry

Explore the largest companies by market capitalization, revenue, income, and employees within the Biotechnology & Pharmaceuticals industry

Classification: SIC NAICS ISIC Available under Commercial License
TTM data as of: September 28, 2026
Total Market Cap
$ 923B
Billions USD (aggregate)
Total Revenue (TTM)
$ 115B
Trailing twelve months
Total Net Income (TTM)
$ -12B
Trailing twelve months
Total Employees
92,805
Headcount (aggregate)
API endpoints for this dataset
https://api.csimarket.com/api/v1/industries/801/list
Programmatic access for models, analytics, and integration workflows.

Explore the largest companies by market capitalization, revenue, income, and employees within the Biotechnology & Pharmaceuticals industry

Company Market Cap
(Millions)
Revenue TTM
(Millions)
Net Income TTM
(Millions)
Employees
Total Biotechnology & Pharmaceuticals Industry $ 923,457 $ 114,547 $ -11,994 92,805
201 more companies available

Sign in to unlock the full Biotechnology & Pharmaceuticals Industry dataset.

Industry Benchmarking Dataset for Institutional Use

Commercial

The data presented above is part of our institutional-grade Industry Benchmarking Dataset, designed for integration into credit risk models, AML/KYC frameworks, portfolio analytics, and internal banking systems. The full dataset is available under a Commercial License, with delivery via API or bulk CSV datasets.

Advanced Metrics & Analytics
  • Multi-year CAGRs & growth acceleration signals
  • Volatility measures & trend stability indicators
  • Cross-sectional percentiles (median, p25, p75)
  • Dispersion metrics (std deviation, spread)
  • Composite scores (growth quality, distress risk)
Institutional Use Cases
  • Credit underwriting & peer benchmarking
  • AML / KYC financial validation
  • Portfolio monitoring & risk tracking
  • Quantitative modeling & factor construction
  • Sector risk & supply chain exposure analysis
Data Delivery
API Access
Real-time endpoints delivering data into risk engines, models, and internal systems.
Bulk CSV Datasets
Pre-structured datasets optimized for direct ingestion into data warehouses, enabling large-scale modeling, backtesting, and historical analysis.
Licensing
Available under institution-grade licensing frameworks with defined usage rights, distribution scope, and integration permissions, supporting internal use, client reporting, and enterprise-wide deployment.
CSIMarket - Industry Benchmarking Data - Per Industry

Institutional-grade industry datasets
in standardized CSV format

Pre-cleaned, audit-ready benchmarking data for this industry - 6 CSV files covering profitability, growth, valuation, efficiency, management effectiveness, and financial strength. Each file delivers 20 quarters and 5 fiscal years of history, with statistical distributions and composite scores per period.

6CSV files
3,880Quarterly endpoints
360Annual endpoints
20Quarters of history
5Fiscal years
Profitability
37 quarterly - 10 annual indicators 790 endpoints ?
Growth
31 quarterly - 7 annual indicators 1,455 endpoints ?
Valuation
29 quarterly - 10 annual indicators 630 endpoints ?
Efficiency
16 quarterly - 12 annual indicators 380 endpoints ?
Management
20 quarterly - 16 annual indicators 480 endpoints ?
Fin. Strength
21 quarterly - 17 annual indicators 505 endpoints ?
Total dataset size - across 110 industries
Quarterly data points
388,000
3,880 × 110 industries
Annual data points
36,000
360 × 110 industries
Industries covered
110
all sectors
Total data points
424,000
quarterly + annual
Industry classification systems supported
CSIMarket Proprietary classification optimized for financial benchmarking and industry analytics
NAICS North American Industry Classification System - used by U.S., Canada & Mexico federal agencies
SIC Standard Industrial Classification - legacy system used by the SEC and financial regulators
ISIC International Standard Industrial Classification - UN framework for global economic comparison
Dataset 1 - Profitability Benchmarks

Margin benchmarks across the full industry distribution

Gross, operating, EBITDA, pre-tax, net, and free cash flow margins - delivered as TTM, quarterly, and annual series with P25 / median / P75 / standard deviation for every reporting period.

Net margin (TTM Q4)
7.44%
+2.11pp vs prior yr
Gross margin
10.44%
industry avg
FCF margin
13.66%
strong
Companies reported
31
Q4 2025
Data coverage per industry
Quarterly indicators
37
metrics per period
Annual indicators
10
fiscal year metrics
Quarterly endpoints
740
20 quarters × 37
Annual endpoints
50
5 fiscal years × 10
Gross, operating, EBITDA, net & FCF margins
TTM, quarterly & fiscal year series
P25 / median / P75 / std dev per period
YoY margin change & acceleration
Effective tax rate & pre-tax margin
Profitability composite score (0–100)
Report preview - Profitability Benchmarks - Aerospace & Defense
Profitability Benchmarks report sample
Dataset 2 - Growth Dynamics

Revenue, income & cash flow growth across 13+ line items

Industry-level growth benchmarks for every major P&L and cash flow line - with breadth indicators showing what share of companies posted positive growth, acceleration metrics, and rolling TTM comparisons.

Revenue growth (TTM Q4)
12.84%
improving
Net income growth
18.45%
above revenue
FCF growth
13.60%
strong
EPS acceleration
+3.69pp
vs prior TTM
Data coverage per industry
Quarterly indicators
31
metrics per period
Annual indicators
7
fiscal year metrics
Quarterly endpoints
1,420
20 quarters × 31
Annual endpoints
35
5 fiscal years × 7
Revenue, gross, EBIT & operating income growth
Net income, EPS (basic & diluted) growth
FCF, net cash flow & CapEx growth
Breadth: % of companies with positive growth
QoQ, YoY, TTM & 3-year CAGR
Growth composite score (0–100)
Report preview - Growth Dynamics - Aerospace & Defense
Growth Dynamics report sample
Dataset 3 - Valuation Multiples

Industry valuation multiples with 5-year context & Z-scores

P/E, P/S, P/FCF, P/Book, EV/EBITDA - current and trailing - with five-year averages, percentile ranks, Z-scores, and a composite valuation score to place the industry in historical context.

P/E ratio (current)
22.4x
vs 5yr avg 14.2x
EV/EBITDA (TTM)
13.1x
P25–P75: 4.5x–20.4x
Earnings yield
4.46%
attractive
Composite val. score
61.7
moderately valued
Data coverage per industry
Quarterly indicators
29
metrics per period
Annual indicators
10
fiscal year metrics
Quarterly endpoints
580
20 quarters × 29
Annual endpoints
50
5 fiscal years × 10
P/E, P/S, P/CF, P/FCF, P/Book multiples
EV/EBITDA & EV/Sales (current & TTM)
5-year historical average per multiple
Z-scores & percentile ranks
Earnings yield & FCF yield
Composite valuation score (0–100)
Report preview - Valuation Multiples - Aerospace & Defense
Valuation Multiples report sample
Dataset 4 - Operational Efficiency

Productivity, turnover ratios & cash conversion benchmarks

Revenue and income per employee, asset and receivables turnover, days sales outstanding, days inventory, days payables, and the full cash conversion cycle - benchmarked across the industry distribution.

Revenue / employee
$487K
improving
Asset turnover
0.61x
P75: 0.80x
Cash conv. cycle
113 days
above avg
Efficiency score
68.7
composite 0–100
Data coverage per industry
Quarterly indicators
16
metrics per period
Annual indicators
12
fiscal year metrics
Quarterly endpoints
320
20 quarters × 16
Annual endpoints
60
5 fiscal years × 12
Revenue & net income per employee
Asset, receivables & inventory turnover
DSO, DIO, DPO & cash conversion cycle
Working capital per revenue
YoY & TTM trend for all metrics
Efficiency composite score (0–100)
Report preview - Operational Efficiency - Aerospace & Defense
Operational Efficiency report sample
Dataset 5 - Management Effectiveness

ROA, ROE, ROIC & DuPont decomposition benchmarks

Return metrics measuring how effectively management allocates capital - with incremental ROIC, DuPont decomposition, FCF quality indicators, and a composite management effectiveness score across the industry.

Return on assets
5.05%
vs 4.44% prior
Return on equity
14.22%
improving
ROIC (TTM)
9.77%
P75: 12.4%
Effectiveness score
72.4
composite index
Data coverage per industry
Quarterly indicators
20
metrics per period
Annual indicators
16
fiscal year metrics
Quarterly endpoints
400
20 quarters × 20
Annual endpoints
80
5 fiscal years × 16
ROA, ROE & ROIC - TTM & quarterly
Incremental ROIC & capital intensity
DuPont 3-factor decomposition
FCF conversion quality metrics
P25 / median / P75 / std dev per metric
Management effectiveness composite (0–100)
Report preview - Management Effectiveness - Aerospace & Defense
Management Effectiveness report sample
Dataset 6 - Financial Strength

Leverage, liquidity & debt coverage across the industry

Debt-to-equity, interest and debt coverage, quick ratio, working capital, leverage ratios - full distribution statistics - in standardized, audit-ready format suited for credit workflows, compliance, and ESG reporting.

Debt / equity (TTM)
1.44x
above industry avg
Interest coverage
8.32x
comfortable
Quick ratio
0.91x
vs P75 1.18x
Fin. strength score
58.4
composite 0–100
Data coverage per industry
Quarterly indicators
21
metrics per period
Annual indicators
17
fiscal year metrics
Quarterly endpoints
420
20 quarters × 21
Annual endpoints
85
5 fiscal years × 17
Quick ratio & working capital ratio
Total & LT debt-to-equity
Leverage & tangible leverage ratios
Interest & debt coverage ratios
P25 / median / P75 / std dev per metric
Financial strength composite score (0–100)
Report preview - Financial Strength - Aerospace & Defense
Financial Strength report sample
Methodology
1. Data Coverage & Universe
Structured dataset built from publicly listed companies, classified across industries, sectors, and total market using CSIMarket, NAICS, SIC, and ISIC frameworks.

Includes up to 5 years of quarterly data (TTM, quarterly, annualized) with continuous updates during earnings cycles.

Coverage transparency includes total companies, reported companies per metric, and coverage ratios.
2. Aggregation Methodology
Industry metrics are calculated using aggregated financial statements, not averages.

Sum-based aggregation is applied to revenue, income, assets, and debt, with market-cap weighting for valuation metrics and TTM normalization to reduce seasonality.

Example: P/E = Total Market Cap ÷ Total Net Income.
3. Ratio Construction
Ratios are standardized and calculated at the company level, then benchmarked across industries.

Covers profitability, valuation, financial strength, efficiency, and growth metrics including margins, ROE, EV multiples, leverage ratios, and CAGR growth measures.
4. Distribution Analytics
Full cross-sectional distribution analysis includes median (P50), quartiles (P25/P75), standard deviation, and interquartile range.

Enables detection of outliers, dispersion, and structural differences within industries.
5. Percentile Rankings
Metrics are normalized into 0–100 percentile rankings using cross-industry PERCENT_RANK().

Direction is adjusted by metric (higher = better for growth/profitability, lower = better for leverage/risk).

Used for benchmarking, factor models, and relative analysis.
6. Volatility & Trend Metrics
Includes volatility (e.g., 8-quarter standard deviation), trend slopes, and growth consistency metrics.

Captures earnings stability, margin durability, and cyclicality across industries.
7. Composite Scores
Multi-factor composite scores (0-100 scale) combine normalized inputs using weighted models.

Includes valuation, growth quality, financial strength, and distress risk scores.
8. Data Quality Controls
Data undergoes standardization, outlier detection, consistency checks, and coverage-based filtering.

Reporting counts and coverage ratios are provided for transparency.
9. Update Frequency
Dataset is continuously updated during earnings seasons.

TTM metrics are recalculated with each new filing, reflecting the most recent reported data.
10. Use Cases
Designed for credit risk analysis, AML/KYC validation, portfolio monitoring, quantitative modeling, and benchmarking workflows.
11. Licensing & Access
Free preview available for evaluation. Full dataset access requires a commercial license.

API and bulk delivery options available for system integration.

Recent News from The Largest Companies in Biotechnology & Pharmaceuticals Industry

Business Update
“Zura Bio Limited Navigating Financial Waters with Resilience in Q3 2025�

Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates In a recent announcement, Zura Bio Limited (NASDAQ: ZURA) reported its financial results for the third quarter of 2025, revealing critical insights into the company’s performance and strategic direction. With 94.29 million shares outstanding, Zura Bio has established its ...

Nov 13, 2025 • Biotechnology and Pharmaceuticals Industry
ZURA
Clinical Study
Humacyte Highlights Innovative Progress in Bioengineered Tissues at Major Vascular Events A New Era for Vascular Surg...

In an exceptional showcase of innovation and scientific advancement, Humacyte, Inc. (Nasdaq: HUMA), a pioneering biotechnology company dedicated to the development of bioengineered human tissues, has announced its participation in the prestigious 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques, and Horizons (VEITHsymposium). Schedule...

Nov 13, 2025 • Biotechnology and Pharmaceuticals Industry
HUMA
Product Service News
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes

Century Therapeutics Unveils Ambitious Beta Islet Program Aiming to Transform Type 1 Diabetes TreatmentPharmaceutical innovation is often heralded by a blend of promise and peril, especially in a field as complex as diabetes research. On November 13, 2025, Century Therapeutics, Inc., a Philadelphia-based biotechnology firm, took a significant step in thi...

Nov 13, 2025 • Biotechnology and Pharmaceuticals Industry
IPSC
Clinical Study
Advances in Alzheimer’s Disease Treatment Cognition Therapeutics Completes Phase 2 Study Enrollment for Zervimesine...

Alzheimer s disease (AD) stands as one of the most pressing public health challenges of our era, with trajectories marked by increasing prevalence rates among aging populations. In response to this crisis, Cognition Therapeutics, Inc. has made significant strides in developing novel therapeutic agents targeting the underlying pathophysiology of AD. This ...

Nov 13, 2025 • Biotechnology and Pharmaceuticals Industry
CGTX
Business Update
Agenus Pushes Frontiers Compassionate Access, Global Trials, and AI Innovations Lead Q3 Advancements,

Agenus Inc. Reports Q3 2025 Achievements: Regulatory Progress, New Data Revelations, and AI-Driven Collaborations LEXINGTON, Mass. Agenus Inc. (Nasdaq: AGEN) has announced its financial results for the third quarter of 2025, showcasing significant clinical and regulatory advancements. These developments reflect the company s commitment to innovative solut...

Nov 10, 2025 • Biotechnology and Pharmaceuticals Industry
AGEN
Clinical Study
AIM ImmunoTech Pioneering Combinatorial Therapies in Oncology and Infectious Disease

In the evolving landscape of oncology and infectious disease management, AIM ImmunoTech Inc. (NYSE American: AIM) has recently captured attention by detailing significant findings from completed clinical trials. The company, primarily known for its innovative immunotherapy, Ampligen (rintatolimod), has contributed to our understanding of treatment modalit...

Nov 10, 2025 • Biotechnology and Pharmaceuticals Industry
AIM
Clinical Study
Advancements in Oncology Mecbotamab Vedotin (Mec-V) Shows Promising Survival Rates in Refractory Soft Tissue Sarcomas

Recent advancements in the field of oncology have introduced novel therapies aimed at improving survival outcomes for patients with refractory soft tissue sarcomas, a notoriously difficult-to-treat group of tumors. Among these, bio-therapeutic innovations such as Mecbotamab Vedotin (Mec-V), an antibody-drug conjugate (ADC) targeting the AXL receptor, have...

Nov 7, 2025 • Biotechnology and Pharmaceuticals Industry
BCAB
Clinical Study
Precision Immunotherapy Coherus Oncologys CHS-114 Showcases Targeted Efficacy in HNSCC

In the ever-evolving landscape of cancer immunotherapy, the latest data unveiled by Coherus Oncology at the Society for Immunotherapy of Cancer (SITC) conference highlights a promising leap forward in precision medicine. CHS-114, a groundbreaking anti-CCR8 cytolytic antibody, demonstrates significant potential in altering the immune microenvironment of he...

Nov 7, 2025 • Biotechnology and Pharmaceuticals Industry
CHRS
Clinical Study
Efficacy of Allo-iNKT Cell Therapy agenT-797 in PD-1 Refractory Solid Tumors Findings from SITC 2025

: MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on innovative allogeneic invariant natural killer T (allo-iNKT) cell therapies, showcased promising clinical data on its lead candidate, agenT-797, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The findings indicate durable responses and significant immu...

Nov 7, 2025 • Biotechnology and Pharmaceuticals Industry
INKT
Business Update
Gileads ASCENT-07 Study Hits a Snag While Financially Staying Afloat in Competitive Waters,

Gilead s ASCENT-07 Study Update: A Mixed Bag Amidst Competitive Pressure in the Pharmaceutical Sector Foster City, California - Gilead Sciences, Inc. (Nasdaq: GILD) has recently provided an update regarding its Phase 3 ASCENT-07 study, which aimed to evaluate the efficacy of Trodelvy (sacituzumab govitecan-hziy) as a first-line treatment in patients with ...

Nov 7, 2025 • Biotechnology and Pharmaceuticals Industry
GILD
Announcement
Alvotech Secures Key Market Authorizations for Biosimilar Gobivaz as Industry Eyes Financial Results

Reykjavik, Iceland and London, UK In a notable stride for the biosimilars industry, Alvotech, a global leader in the development and manufacture of biosimilar medicines, and its partner Advanz Pharma have successfully secured marketing authorizations from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Gobivaz, their biosimilar to S...

Nov 7, 2025 • Biotechnology and Pharmaceuticals Industry
ALVO
Clinical Study
“Emerging Innovations in Hepatitis B Treatment Immunocores Promising Phase 1 Data on IMC-I109V�

Immunocore Presents Phase 1 Data for Hepatitis B Candidate at AASLD s The Liver Meeting In an era marked by remarkable advances in therapeutic strategies, Immunocore has taken a significant step forward in the battle against hepatitis B. At the prestigious American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, held recently, the b...

Nov 7, 2025 • Biotechnology and Pharmaceuticals Industry
IMCR
Clinical Study
ProKidneys Rilparencel Phase 2 Triumph Navigating CKD Treatment Landscape Amid Revenue Stagnation and Competitive ...

The landscape of chronic kidney disease (CKD) therapeutics is rapidly evolving, with emerging cell therapies offering new hope for patients suffering from advanced stages of the disease. At the forefront of this innovation is ProKidney Corp. (Nasdaq: PROK), a late clinical-stage cell therapy company dedicated to addressing the dire unmet needs of CKD pati...

Nov 6, 2025 • Biotechnology and Pharmaceuticals Industry
PROK
Clinical Study
In a significant advancement in the field of precision medicine, Tevogen Bio Holdings Inc. (Nasdaq TVGN) ha...

Tevogen Bio Expands HLA Coverage for Precision T Cell Therapy in Major Clinical Milestone In a significant advancement in the field of precision medicine, Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has announced a major clinical milestone in its investigational T cell therapy program. The company reported the completion of T cell target identification for a...

Nov 6, 2025 • Biotechnology and Pharmaceuticals Industry
TVGN
Clinical Study
Revolution Medicines Advances RAS-Targeted Therapies in Oncology Third Quarter Financial Results and Clinical Updates

for CSIMarket.com Revolution Medicines, Inc., a late-stage clinical oncology company based in Redwood City, California, recently reported its financial results for the third quarter of 2025 and provided significant updates on its pipeline of targeted therapies aimed at treating RAS-addicted cancers. Financial Overview For the quarter ending Septembe...

Nov 6, 2025 • Biotechnology and Pharmaceuticals Industry
RVMD
Clinical Study
Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation

Pioneering Discussions: Mesoblast Poised for FDA Meeting on Rexlemestrocel-L and Opioid CessationIn a significant step towards revolutionising pain management, Mesoblast Limited (Nasdaq: MESO; ASX: MSB), a global frontrunner in allogeneic cellular medicines for inflammatory diseases, has announced its upcoming meeting with the U.S. Food and Drug Administ...

Nov 5, 2025 • Biotechnology and Pharmaceuticals Industry
MESO
Announcement
Alvotech Under Investigation for Potential Securities Fraud as Company Engages with Investors

New York-based Kirby McInerney LLP has announced an investigation into Alvotech, a biotechnology firm listed on NASDAQ under the ticker ALVO, for potential securities fraud. The law firm is scrutinizing whether Alvotech may have violated federal securities laws or participated in any other unlawful business activities.This investigation comes at a crucial...

Nov 5, 2025 • Biotechnology and Pharmaceuticals Industry
ALVO
Clinical Study
Compass Therapeutics Charts a Course Scientific Innovation Meets Market Challenges with CTX-10726,

In the rapidly evolving field of oncology, biopharmaceutical companies are continuously striving to break new ground and deliver innovative therapies to patients confronting cancer. Compass Therapeutics, Inc. (Nasdaq: CMPX) stands at an intriguing intersection of scientific advancement and market dynamics as they recently unveiled promising preclinical da...

Nov 4, 2025 • Biotechnology and Pharmaceuticals Industry
CMPX
Clinical Study
Ampligen From Cancer to Viral Defense, A Frontier of Therapeutic Innovation,

Ampligen: A Promising Player in the Fight Against Cancer and Viral Infections AIM ImmunoTech Inc. continues to push the frontiers in the field of immunotherapy, with a series of compelling announcements highlighting the utility of Ampligen (rintatolimod) in combating difficult-to-treat diseases. The latest revelations about Ampligen were showcased in a la...

Nov 4, 2025 • Biotechnology and Pharmaceuticals Industry
AIM
Announcement
Alvotech Prepares for Strategic Financial Update Amid Promising Industry Developments

Alvotech (NASDAQ: ALVO), a leading global biotech company focused on developing and manufacturing biosimilar medicines, has recently made significant announcements concerning its financial performance and strategic engagements. As the company approaches its webcast and conference calls slated for November 2025, the market watches closely to assess the pot...

Nov 4, 2025 • Biotechnology and Pharmaceuticals Industry
ALVO
Product Service News
Navigating the Regulatory Landscape Alvotechs Recent Developments with BIOSIMILARS

In the dynamic realm of biopharmaceuticals, regulatory challenges and breakthroughs can dramatically reshape the landscape for companies involved in drug development. Alvotech, a global biotech company specializing in the manufacture of biosimilar medicines, recently encountered significant regulatory hurdles while also celebrating a notable success. This...

Nov 3, 2025 • Biotechnology and Pharmaceuticals Industry
ALVO
Product Service News
Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025

Breakthrough and Challenges: Molecular Partners Unveils Pioneering Preclinical Data Amidst Financial Hurdles ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. November 3, 2025 In an exciting development for the field of cancer immunotherapy, Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotechnology powerhouse, has presented furt...

Nov 3, 2025 • Biotechnology and Pharmaceuticals Industry
MOLN
Business Update
QIAGEN Reaches Key Milestone with 4,000th QIAcube Connect Placement Amidst Revenue Challenges,

QIAGEN Celebrates 4,000th QIAcube Connect Placement, Reinforcing Commitment to Automated Sample Processing In a major development within the life sciences and diagnostics sectors, QIAGEN N.V., headquartered in Venlo, Netherlands, and Germantown, Maryland, has achieved a significant milestone with the placement of its 4,000th QIAcube Connect instrument. Th...

Oct 29, 2025 • Biotechnology and Pharmaceuticals Industry
QGEN
Clinical Study
Kyverna Therapeutics KYV-101 A Breakthrough in Myasthenia Gravis Treatment Poised to Redefine the Future,

Breaking New Ground in Myasthenia Gravis Treatment: Positive Phase 2 Data from KYV-101 Study Marks a Milestone for Kyverna Therapeutics Compelling Results Set New Clinical Standard in Generalized Myasthenia Gravis (gMG), Raising Confidence for Upcoming Phase 3 Trial Kyverna Therapeutics Inc. (NASDAQ: KYTX) has recently announced encouraging interim resul...

Oct 29, 2025 • Biotechnology and Pharmaceuticals Industry
KYTX
Clinical Study
Breaking New Ground in Cancer Therapy IN8bios INB-100 Trial Welcomes The Ohio State University,

Expanding Horizons in Cancer Immunotherapy: IN8bio Welcomes The Ohio State University to the INB-100 Phase 1 Clinical Trial The pursuit of innovative cancer treatments takes another encouraging stride as IN8bio, a prominent biotechnology company focused on developing groundbreaking gamma-delta T cell therapies, has announced the expansion of its INB-100 P...

Oct 29, 2025 • Biotechnology and Pharmaceuticals Industry
INAB
Business Update
Gilead Sciences to Present Promising Long-Term Efficacy Data at The Liver Meeting 2025 Amidst Mixed Financial Perform...

Gilead Sciences, Inc. (Nasdaq: GILD) is positioning itself at the forefront of liver disease research with its upcoming presentation at The Liver Meeting 2025, an event organized by the American Association for the Study of Liver Diseases (AASLD) scheduled for November 7-11 in Washington, D.C. The company plans to unveil notable findings from over 35 acce...

Oct 23, 2025 • Biotechnology and Pharmaceuticals Industry
GILD
Clinical Study
Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a...

Alector s Advancements and Challenges in Neurodegenerative Therapies: A Comprehensive Update SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 Alector, Inc. (Nasdaq: ALEC), a prominent clinical-stage biotechnology firm, continues to navigate the complex landscape of neurodegenerative disease treatment. The company, which specializes in creating therapies aim...

Oct 21, 2025 • Biotechnology and Pharmaceuticals Industry
ALEC
Clinical Study
Telitacicept Takes Center Stage Pioneering Hope for IgA Nephropathy at ASN Kidney Week 2025,

Transformative Advances in IgA Nephropathy: Vor Bio s Promising Phase 3 Clinical Data Presentation at ASN Kidney Week 2025 In a groundbreaking development that is set to captivate the nephrology community, Vor Bio, a prominent clinical-stage biotechnology entity specializing in the treatment of autoimmune diseases, has announced a significant clinical mil...

Oct 20, 2025 • Biotechnology and Pharmaceuticals Industry
VOR
Announcement
AI-Driven Success Evaxion’s Cancer Vaccine Achieves 75% Response Rate Amid Financial Challenges,

Revolutionizing Cancer Treatment: Evaxion s AI-designed Vaccine Achieves Breakthrough Results In a remarkable stride for cancer treatment, Evaxion A/S, a clinical-stage TechBio leader, has announced unprecedented efficacy data from its personalized cancer vaccine, EVX-01, in a Phase 2 trial targeting advanced melanoma. This announcement made on October 17...

Oct 20, 2025 • Biotechnology and Pharmaceuticals Industry
EVAX
Business Update
Advancing Oncology Breakthrough Survival Outcomes with Botensilimab and Balstilimab Combination in Refract...

In the rapidly evolving field of immuno-oncology, Agenus Inc. (Nasdaq: AGEN) has marked a significant milestone with the presentation of new data demonstrating promising survival outcomes for patients with advanced-stage cancer undergoing treatment with a combination of botensilimab (BOT) and balstilimab (BAL). This novel therapeutic combination has emer...

Oct 20, 2025 • Biotechnology and Pharmaceuticals Industry
AGEN

Decision Framework & Data Access

Power onboarding, benchmarking, and quantitative analysis with institutional-grade datasets structured for direct integration into financial models and risk frameworks.

  • Industry benchmarking datasets (valuation, growth, profitability)
  • Designed for quant models, AML/KYC validation & onboarding workflows
  • Consistent time-series structure (Quarterly, TTM, Annual)
  • Coverage across 100+ industries and 20+ years of history
CSV - SFTP - REST API - Daily Updates - Integration-ready for Python, R & BI tools